

URO17[®]

Bladder Cancer Detection

About URO17[®]

- Non-Invasive Urine Test
- Reimbursed by Applicable CPT Codes
- High sensitivity and NPV*
- Detects both Low and High grade

*Babu et al. 2019. Modern Pathology. Vasdev et al. 2020. Babu et al 2021

Risk Stratification*

- Negative Cytology/Negative URO17 → No to Low Risk of Bladder Cancer
- Atypical Cytology/Negative URO17 → No to Low Risk of Bladder Cancer
- Negative Cytology/High URO17 Expression → Standard Diagnostic Workup is Recommended
- Atypical Cytology/High URO17 Expression → Standard Diagnostic Workup is Recommended

*Developed by a panel of Urology Specialists and Scientific Advisors

**URO17 is available as a Lab Developed Test (LDT) for use in the USA and CE-IVD for outside USA.

For more information, please contact us at: info@kdxdiagnostics.com

KDx Diagnostics, Inc. 408.628.7715 KDxDiagnostics.com URO17test.com

KDx-405 Rev. A



Clinical Applications**

Hematuria
NMIBC Follow Up
High Risk Group
(Smokers, Chemical Exposure,
Veterans, Family History)

